Guizhou Bailing (002424) First Coverage Report: Marketing Reform Exhibition New Bureau Seedling Drug Leader opens a new chapter
Guizhou BaiLing (002424) First Coverage Report: Leading Pharmaceutical Products, Rich Brand Promotions, Strong Innovative Varieties Overlapping
Guizhou Bailing (002424): Clinical trial results from PLA General Hospital suggest that glycosine conjugation capsules have a certain effect on restoring pancreatic islet beta cell function
Guizhou Bailing (002424): Foreign Investment Rating Report (Overseas Institutional Investment Rating C)
Guizhou BaiLing (002424) First Coverage Report: Miao Drug Integration Project Continues to Advance
Guizhou BaiLing (002424) In-depth Research: Leading Medicine Protects Human Health
Guizhou bailing (002424): the performance is in line with the expected strategy to buy shares in Yunzhi Pharmaceutical Co., Ltd.
Guizhou bailing (002424): join hands with Guanganmen Hospital of traditional Chinese Medicine to steadily promote the national layout of Tangning Tongluo.
Guizhou bailing (002424): the Diabetes Hospital expands the layout of the Southwest Medical City of Chengdu.
Guizhou bailing (002424) Company Research: performance meets expectations Tangning Tongluo starts clinical trial in 301Hospital
Comments on Guizhou lark (002424) Annual report: revenue maintains rapid growth and high input breeds new hope
Guizhou Bailing (002424) Interim Report: Revenue Maintains Rapid Growth, and Medical Services Develop Rapidly
Guizhou Bailing (002424) Annual Report Review: Performance Growth Meets Expectations Diabetes Industry Chain
Guizhou Bailing (002424) Research Brief: Miao Pharmaceutical Leaders Build a Comprehensive Diabetes Treatment Service Industry Chain
[Huachuang Securities] Guizhou Bailing: Leading Miao Drug, Building a Comprehensive Diabetes Treatment Service Industry Chain
Guizhou Bailing (002424) Research Report: Performance Growth Is Impressive, Progress in Chronic Disease Management in Guizhou Exceeds Expectations
[Bohai Securities] Guizhou Bailing Research Report: Performance growth is impressive, progress in chronic disease management in Guizhou exceeds expectations
Guizhou Bailing (002424) In-depth study: the leading drug drug layout from medicine to medicine
[Shen Wan Hongyuan] Guizhou Bailing: Steady operation and steady revenue growth
贵州百灵(002424)年报点评:经营稳健 营收保持稳步增长
No Data